web analytics

Cambridge University: PARP-inhibitors | A New Generation of Cancer Drugs

Click to enlarge video or view it below.

First of new generation of cancer drugs granted European approval

A new drug for ovarian cancer, developed by researchers at the University of Cambridge and AstraZeneca, has become the first of new class of drugs, known as PARP-inhibitors, to be granted approval anywhere in the world. The drug, Lynparza, has been granted Marketing Authorisation from the European Commission.